Another Big Pharma CEO faces the prospect of appearing before a jury to testify in defense of a drug that has been called dangerous.
Johnson & Johnson appears to be in settlement mode. It has knocked off some more pending litigation, having settled about 25% of the 3,400 lawsuits it faced tied to the dangers of taking antibiotic Levaquin. The settlements come after it recently negotiated settlements related to its aggressive marketing of antipsychotic drug Risperdal.
Pfizer doesn't want CEO Ian Read to take the stand in a Chantix liability suit. That's not unusual; Johnson & Johnson fought a request that CEO Alex Gorsky testify in person in a trial over alleged Risperdal misconduct. What's different in Pfizer's case is that a judge actually ordered Read to appear.
Johnson & Johnson has again backed down on its defense of Risperdal cases alleging that it caused boys who were given the antipsychotic to grow breasts.
Lawyers are pulling no punches in that Risperdal litigation playing out in Philadelphia court. After trying to force Johnson & Johnson CEO Alex Gorsky onto the stand to talk about the company's Risperdal marketing practices, plaintiff's attorneys want ex-FDA chief David Kessler to testify--and Kessler is on record saying that J&J's Janssen unit broke the law by marketing Risperdal off-label.
With every Risperdal trial--and there have been more than a few--we hear new allegations about Johnson & Johnson ($JNJ) marketing techniques. This time, we're looking at a patient liability suit, one of many that attempt to link Risperdal use with boys' breast development.
Johnson & Johnson ($JNJ) CEO Alex Gorsky has again dodged a bullet and will not be forced to testify in front of a jury in the somewhat sensational Risperdal case in which a teenage boy allegedly grew breasts after taking the antipsychotic drug.
Should Johnson & Johnson ($JNJ) CEO Alex Gorsky have to take the stand in a Risperdal liability case? Lawyers for a Texas teen suing the company are demanding Gorsky's presence in court, saying he is well aware of J&J's Risperdal marketing tactics because he ran the unit that sold the drug.
The company may have reached a settlement over the marketing of drug Risperdal, but won't admit it did anything wrong.
Just as Johnson & Johnson is wrapping up its long-running Risperdal marketing investigation, the feds are eyeing its promotions for another drug: its antibiotic Doribax. The U.S. Justice Department demaded Doribax marketing information in April, J&J disclosed in its latest filing with the Securities and Exchange commission.